Mouse models of prostate cancer: picking the best model for the question

被引:0
作者
Magdalena M. Grabowska
David J. DeGraff
Xiuping Yu
Ren Jie Jin
Zhenbang Chen
Alexander D. Borowsky
Robert J. Matusik
机构
[1] Vanderbilt University,
[2] Meharry Medical College,undefined
[3] University of California Davis,undefined
来源
Cancer and Metastasis Reviews | 2014年 / 33卷
关键词
Mouse models; Prostate cancer; TRAMP; LADY; PTEN; Myc;
D O I
暂无
中图分类号
学科分类号
摘要
When the National Institutes of Health Mouse Models of Human Cancer Consortium initiated the Prostate Steering Committee 15 years ago, there were no genetically engineered mouse (GEM) models of prostate cancer (PCa). Today, a PubMed search for “prostate cancer mouse model” yields 3,200 publications and this list continues to grow. The first generation of GEM utilized the newly discovered and characterized probasin promoter driving viral oncogenes such as Simian virus 40 large T antigen to yield the LADY and TRAMP models. As the PCa research field has matured, the second generation of models has incorporated the single and multiple molecular changes observed in human disease, such as loss of PTEN and overexpression of Myc. Application of these models has revealed that mice are particularly resistant to developing invasive PCa, and once they achieve invasive disease, the PCa rarely resembles human disease. Nevertheless, these models and their application have provided vital information on human PCa progression. The aim of this review is to provide a brief primer on mouse and human prostate histology and pathology, provide descriptions of mouse models, as well as attempt to answer the age old question: Which GEM model of PCa is the best for my research question?
引用
收藏
页码:377 / 397
页数:20
相关论文
共 819 条
[21]  
Huang J(2008)Small cell carcinoma of the prostate: a morphologic and immunohistochemical study of 95 cases The American Journal of Surgical Pathology 32 65-71
[22]  
Radaelli E(2007)Unusual and underappreciated: small cell carcinoma of the prostate Seminar in Oncology 34 22-29
[23]  
Martin P(2006)Sarcomatoid carcinoma of the prostate: a study of 42 cases American Journal of Surgical Pathology 30 1316-1321
[24]  
Signoretti S(2011)Prostate epithelial Pten/TP53 loss leads to transformation of multipotential progenitors and epithelial to mesenchymal transition The American Journal of Pathology 179 422-435
[25]  
Sullivan R(2007)Inducible FGFR-1 activation leads to irreversible prostate adenocarcinoma and an epithelial-to-mesenchymal transition Cancer Cell 12 559-571
[26]  
Ousset M(2012)Pten loss and RAS/MAPK activation cooperate to promote EMT and metastasis initiated from prostate cancer stem/progenitor cells Cancer Research 72 1878-1889
[27]  
Van Keymeulen A(2012)Initiation of prostate cancer in mice by Tp53R270H: evidence for an alternative molecular progression Disease Models & Mechanisms 5 914-920
[28]  
Bouvencourt G(2011)Determining prostate cancer-specific death through quantification of stromogenic carcinoma area in prostatectomy specimens The American Journal of Pathology 178 79-87
[29]  
Sharma N(2003)Reactive stroma as a predictor of biochemical-free recurrence in prostate cancer Clinical Cancer Research 9 4792-4801
[30]  
Achouri Y(2001)Malignant transformation in a nontumorigenic human prostatic epithelial cell line Cancer Research 61 8135-8142